A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Phase of Trial: Phase II/III
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms Intellance1
- Sponsors AbbVie; AbbVie Germany
- 25 Sep 2019 This trial has been completed in Czech Republic.
- 10 Jul 2019 Planned End Date changed from 24 Jul 2021 to 18 Jul 2020.
- 10 Jul 2019 Planned primary completion date changed from 18 Mar 2020 to 18 Jul 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History